TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26255764
Drug: 5 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 weekly fractions (fx/w) of radiotherapy
Study: 23369174
Drug: Sites group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sites group (treatment)
Study: 18087797
Drug: Buprenorphine 16
Normalized name: buprenorphine 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 16 mg + naloxone 4 mg/day
Study: 11552215
Drug: Aprotinin infusion
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin infusion (1,000,000-KIU loading dose, followed by 250,000-KIU/h infusion during surgery)
Study: 7709944
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g elemental calcium)
Study: 2691233
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg four times daily for a week)
Study: 22292366
Drug: Dengzhan group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengzhan group (fleabane injection and Dengzhan Shengmai capsules)
Study: 16464386
Drug: Urinastatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinastatin treatment (300 kU for severe burns, 200 kU for moderate burns) administered intravenously twice a day for 5 to 7 days
Study: 16464386
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received routine therapy
Study: 15471303
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without protective HI antibody to A (H3N2)
Study: 9349062
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg.kg‐1 followed by infusion of 3 micrograms.kg‐1.min‐1
Study: 9349062
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg.kg‐1 followed by infusion of 10 micrograms.kg‐1.min‐1
Study: 21540760
Drug: 10-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)
Study: 20042092
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber diet (instruction to achieve daily dietary fiber intake of 30 g or more)
Study: 16036076
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PTH with other agents (estrogens, calcitonin, bisphosphonates)
Study: 11451272
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) therapy for 26 weeks
Study: 9331351
Drug: Cocaine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.6 mg/kg)
Study: 7530680
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for metastatic dysgerminoma
Study: 7530680
Drug: Platinum-based combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based combination chemotherapy for OSCST with poor differentiation
Study: 2980866
Drug: naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (10 mg sc)
Study: 25875011
Drug: Visceral osteopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visceral osteopathic treatment (3 times during the first week of life)
Study: 25875011
Drug: Visceral osteopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visceral osteopathic treatment
Study: 14534771
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (Nicotrol)
Study: 9553686
Drug: Patch 7D
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patch 7D (7-day estradiol transdermal patch)
Study: 30589600
Drug: Triptorelin 3.75
Normalized name: triptorelin 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg plus letrozole 2.5 mg/day
Study: 28322071
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with normal bolus insulin and an additional 30% insulin bolus administered 3-h post-meal (HFA)
Study: 28322071
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal with normal bolus insulin
Study: 28322071
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with normal bolus insulin
Study: 24290367
Drug: Donepezil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil treatment
Study: 18331283
Drug: H. perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. perforatum extract (300 mg, hypericin 0.31% and hyperforin 3.0%) taken three times a day for 12 weeks
Study: 17244684
Drug: Oral beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beclomethasone dipropionate (BDP) 8 mg/d for 50 days
Study: 9239399
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg daily for 12 weeks
Study: 11699125
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (immediate denudation, immediate injection)
Study: 11699125
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (delayed denudation, delayed injection)
Study: 7957521
Drug: Intravenous colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colchicine 1 mg (elderly group)
Study: 7957521
Drug: Intravenous colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colchicine (both groups)
Study: 7957521
Drug: Intravenous colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colchicine (healthy group)
Study: 7957521
Drug: Intravenous colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colchicine (elderly group)
Study: 7957521
Drug: Intravenous colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colchicine (healthy volunteers)
Study: 7957521
Drug: Oral colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral colchicine (both groups)
Study: 2824297
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human fibroblast interferon (HuIFN‐beta) 7.5 x 10(5) IU/ml, one drop 5 times daily
Study: 28557747
Drug: Iodide supplementation
Normalized name: Echothiophate Iodide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodide supplementation (sodium iodide, 30 μg/kg per day)
Study: 28557747
Drug: Placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride, 30 μg/kg per day)
Study: 23203140
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g soy protein and 100 mg isoflavones
Study: 23203140
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g milk protein and 100 mg isoflavones
Study: 23203140
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g milk protein
Study: 11094589
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered after 15 min of sevoflurane exposure
Study: 11094589
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered after 30 min of sevoflurane exposure
Study: 11094589
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered after 60 min of sevoflurane exposure
Study: 11094589
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered after 90 min of sevoflurane exposure
Study: 8838440
Drug: Meloxicam 5
Normalized name: meloxicam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 5 mg
Study: 16540287
Drug: Meloxicam 10
Normalized name: meloxicam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 10 mg
Study: 8838440
Drug: Meloxicam 20
Normalized name: bupivacaine-meloxicam 200 mg-6 mg/7 mL injectable solution, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 20 mg
Study: 8838440
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg (i.v.)
Study: 8838440
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg (i.m.)
Study: 1562335
Drug: Enlarging intravenous
Normalized name: GLYCERIN 5 mg in 100 mL CUTANEOUS LOTION [ENLARGING BREASTLOTION]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enlarging intravenous (IV) catheter
Study: 3907425
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg b.i.d.)
Study: 17986525
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg with Amlodipine 5 mg
Study: 11811571
Drug: Creatine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (2 g) in solution
Study: 11811571
Drug: Creatine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine as a lozenge (solid form)
Study: 1724023
Drug: Intravenous droplet
Normalized name: LANCET,DROPLET 30G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous droplet contrykal
Study: 1724023
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with antibacterial and antiproteolytic drugs
Study: 26878894
Drug: Self-help book
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help book with a Cognitive Behavioral Therapy (CBT) program without guidance
Study: 26878894
Drug: CBT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT program emailed weekly by a trained psychologist with personalized guidance
Study: 15023168
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor treatment without surgery (group 2)
Study: 595585
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin (HCG) injections
Study: 17016713
Drug: Lorazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 0.25 mg
Study: 17016713
Drug: Lorazepam (dose-dependent)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam (dose-dependent)
Study: 12654404
Drug: Partially unblinded
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially unblinded active-controlled drug trials
Study: 2608693
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (8 capsules/day)
Study: 2608693
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 capsules)
Study: 24359938
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol
Study: 25724520
Drug: Cetuximab (6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (6-week course, weekly) with cisplatin-based radiochemotherapy
Study: 9209950
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of chemotherapy (5-FU and folinic acid)
Study: 29310653
Drug: High-dose soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose soy lecithin (1200 mg/day)
Study: 29310653
Drug: Low-dose soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose soy lecithin (600 mg/day)
Study: 23946126
Drug: Transtympanic 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transtympanic 2% L‐N‐Acetylcysteine (L‐NAC)
Study: 9568553
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Academic detailing (AD) and Continuous Quality Improvement (CQI) teams
Study: 3055074
Drug: Naloxone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (100 micrograms/kg bolus followed by 50 micrograms/kg/h infusion)
Study: 3055074
Drug: Control (preservatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (preservatives of the naloxone preparation)
Study: 18054688
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulfate, 80 mg/day)
Study: 7959290
Drug: Radical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical therapy (Group A)
Study: 19099919
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (Group B)
Study: 3605694
Drug: d‐tubocurarine pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine pretreatment (0.05 mg/kg) followed by succinylcholine (1.5 mg/kg)
Study: 3605694
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 ml) followed by succinylcholine (1.5 mg/kg)
Study: 3605694
Drug: 0.7 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg of succinylcholine without d‐tubocurarine pretreatment
Study: 3605694
Drug: d‐tubocurarine pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine pretreatment (0.05 mg/kg)
Study: 31982073
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of combined measles-mumps-rubella-varicella vaccine (MMR+V)
Study: 31982073
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of monovalent varicella vaccine
Study: 17323789
Drug: Fingolimod first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod first dose
Study: 21911572
Drug: ACHN-490 injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACHN-490 injection, 1 mg/kg body weight followed by ascending doses of 4, 7, 11, and 15 mg/kg for 10, 10, 5, and 3 days respectively in Study 1
Study: 21911572
Drug: ACHN-490 injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACHN-490 injection, 15 mg/kg for 5 days in Study 2
Study: 17076985
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN) 1000 mg daily for 12 months
Study: 17076985
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN) 1000 mg daily for 24 months
Study: 11527868
Drug: Supervision for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervision for standard treatment guidelines (STG)
Study: 18041485
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolpidem
Study: 31039765
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) + Treatment as Usual (TAU)
Study: 29301585
Drug: Biomarker controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker controlled treatment advisory algorithm
Study: 26801063
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (20 μg) with standard regimen (0-1-6 month)
Study: 26801063
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (60 μg) with 2-dose regimen (0-1 month)
Study: 21792863
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (first-line treatment with chemotherapy followed by gefitinib as second-line treatment)
Study: 19910718
Drug: Paliperidone extended
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended release (3-12 mg/d)
Study: 17389554
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg oral dose
Study: 356738
Drug: Levamisole hydrochloride
Normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole hydrochloride therapy
Study: 31618863
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of protein (C)
Study: 21673045
Drug: Oral periodic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral periodic presumptive treatment (PPT)
Study: 14713918
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg daily and placebo
Study: 9209776
Drug: Sumatriptan 10
Normalized name: sumatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 10 mg
Study: 9209776
Drug: Sumatriptan 20
Normalized name: sumatriptan 20 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 20 mg
Study: 9209776
Drug: Sumatriptan 20
Normalized name: sumatriptan 20 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 20 mg (multiple doses)
Study: 7802852
Drug: Alpidem (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (50 mg, three times a day)
Study: 29861725
Drug: GDM1 (tight
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and < 7.0 mmol/L postprandial)
Study: 29861725
Drug: GDM2 (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDM2 (less tight glycaemic targets, fasting blood glucose < 5.3 mmol/L and < 7.8 mmol/L postprandial)
Study: 23281973
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfusion when hemoglobin fell below 7 g/dL)
Study: 23281973
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusion when hemoglobin fell below 9 g/dL)
Study: 12099389
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (Genotropin) at a dose of 0.2 IU/kg/day for 2 years (Group 1)
Study: 12099389
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for one year after the initial trial (Group 2)
Study: 12099389
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 2) without treatment
Study: 12099389
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after discontinuation of GH therapy
Study: 11286468
Drug: Toremifene (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (40 mg/day)
Study: 7546498
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg isradipine SRO at 08:00
Study: 7546498
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg isradipine SRO at 20:00
Study: 28618005
Drug: Lanabecestat 15
Normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanabecestat 15 mg
Study: 31764959
Drug: Lanabecestat 50
Normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanabecestat 50 mg
Study: 23534542
Drug: Miravirsen 3
Normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miravirsen 3 mg/kg
Study: 23534542
Drug: Miravirsen 5
Normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miravirsen 5 mg/kg
Study: 23534542
Drug: Miravirsen 7
Normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miravirsen 7 mg/kg
Study: 16519546
Drug: Extended adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended adjuvant letrozole (2.5 mg/day)
Study: 30101300
Drug: Long-acting beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta agonist
Study: 27039125
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg
Study: 25263215
Drug: Albiglutide 50
Normalized name: ALBIGLUTIDE 50MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 50 mg
Study: 18700689
Drug: omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omega 3 fatty acid enhanced supplement with a low ratio of omega3/omega6
Study: 15971400
Drug: Short-course chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course chemotherapy
Study: 12418497
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg SAMe
Study: 8804805
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg RU486
Study: 22072548
Drug: G‐CSF/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF/placebo
Study: 22072548
Drug: G‐CSF/DXM
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF/DXM
Study: 16969894
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral treatment
Study: 2768569
Drug: Hydrocolloid membrane
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid membrane treatment
Study: 25367207
Drug: Selective β1‐blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective β1‐blocker metoprolol (40 μg/kg)
Study: 20974318
Drug: Acarbose 150
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 150 mg/d
Study: 15782623
Drug: Peg-interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon alfa-2b 1.5mcg/Kg s.c./once-weekly (group C)
Study: 7954244
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (76.8 Gy or 81.4 Gy)
Study: 7954244
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose (64.8 Gy or 72.0 Gy)